Sector: Pharmaceuticals & Biotechnology - Healthcare
BSE Code: 530057
NSE Symbol: VIVANZA
ISIN: INE984E01035
Vivanza Biosciences Exempt from Annual Secretarial Compliance Report 📋 • Vivanza Biosciences exempt from submitting Annual Secretarial Compliance Report for year ended March 31, 2026 • Exemption based on SEBI Regulation 15(2) for companies with paid-up equity share capital ≤ ₹10 crores and net wo…
📊 Vivanza Biosciences: No Fundraising or Statement Deviation Required • No deviation or variation statement required under SEBI Regulation 32 • No funds raised through public issue, rights issue, preferential issue, or QIP • Confirmation submitted to BSE Limited on April 14, 2026 • Signed by Chai…
📊 Vivanza Biosciences Ltd. Promoter Holdings Update – March 2026 - Hemant A. Parikh held 100,211 shares as of March 31, 2026. - Parth H. Parikh held 7,907,622 shares as of March 31, 2026. - No encumbrance on shares during the financial year. - Disclosures submitted to BSE on April 9, 2026.
📊 Vivanza Biosciences Ltd: Exempt from Initial Debt Disclosure Requirements - Vivanza Biosciences Limited does not qualify as a 'Large Corporate' as of March 31, 2026, per SEBI and BSE criteria. - The company is exempt from filing initial disclosure requirements (Annexure A and Annexure XII A) fo…
📈 Board Update: Hemant Parikh Resigns from Vivanza Biosciences - Mr. Hemant Amrish Parikh (DIN: 00027820) resigned as Non-Executive Director - Resignation tendered and effective March 17, 2026 - Reason cited: personal reasons - No material reasons for resignation beyond those stated
Vivanza Biosciences: No Fundraising & No SEBI Deviation Required 📋 • Vivanza Biosciences has not raised funds through public issue, rights issue, preferential issue, or QIP • No deviation or variation statement is required under SEBI Regulation 32 • Confirmation is based on SEBI Circular CIR/CFD/…
Vivanza Biosciences Q3 2025 Results 📊 Revenue & Profit Growth Highlights • Standalone Q3 2025 revenue: ₹4,493.26 lacs • Standalone 9-month revenue: ₹10,648.51 lacs • Consolidated Q3 2025 revenue: ₹4,525.07 lacs • Consolidated 9-month revenue: ₹10,954.77 lacs • Standalone Q3 2025 profit before tax…
📊 Vivanza Biosciences Q3 FY26 Results Meeting Scheduled • Board meeting scheduled for February 12, 2026 • Agenda includes approval of unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 • Trading window for insiders (directors, officers,…
Vivanza Biosciences Expands into Plastic & Packaging Manufacturing 🏭📦 - Vivanza Biosciences approved an expansion into manufacturing plastic polymer films (25 microns), bags, sacks, and flexible packaging. - New business includes processing materials for food, chemicals, fertilizers, grains, and…
Vivanza Biosciences Shareholders Overwhelmingly Approve MOA Amendment 📊✅ - Special Resolution to alter MOA passed with 99.90% votes in favor (5,106,561 votes) and 0.10% against (4,978 votes). - Total shareholders on record date (07-11-2025): 20,273. - Promoter & Promoter Group voted 100% in favor…
🚀 Vivanza Biosciences Expands into Packaging Materials – Shareholder Vote Ahead! - Vivanza Biosciences proposes expanding into manufacturing plastic polymer films, bags, paper bags, and flexible packaging. - Shareholder voting via Postal Ballot runs from November 17 to December 16, 2025. - Eligib…
Vivanza Biosciences Expands into Packaging & Reports Q3 2025 Results 📊 - Vivanza Biosciences proposes expansion into plastic polymer films, bags, and flexible packaging via shareholder Postal Ballot (voting: Nov 17–Dec 16, 2025). - Q3 2025 standalone revenue: ₹5,373.18 lakhs; consolidated revenue…
Vivanza Biosciences Update: Key SEBI Regulation Not Applicable 📊 - Regulation 23(9) of SEBI (LODR) Regulations, 2015 (related-party transactions) is not applicable for Q2 & H1 ending Sept 30, 2025. - Inapplicability due to paid-up equity share capital of ₹4 crore and net worth of ₹4.02 crore as o…
Vivanza Biosciences: No Fundraising or Regulatory Deviations Reported 📊 - Vivanza Biosciences confirms no deviation or variation under SEBI Regulation 32. - No funds raised via Public Issue, Rights Issue, Preferential Issue, or QIP. - Compliance with SEBI regulations fully maintained. - Official …
Vivanza Biosciences Seeks Shareholder Approval for Key Changes 📋 - Vivanza Biosciences Limited is seeking shareholder approval to alter its main object clause. - The cut-off date for determining eligible voters is November 7, 2025. - Dispatch of the notice via electronic means will be completed b…
Vivanza Biosciences Expands into Packaging & Posts Q3 Results 📊🔄 - Revenue from operations: ₹5,373.18 lakhs (standalone) and ₹5,535.78 lakhs (consolidated) for Q3 (Sept 30, 2025). - Profit before tax: ₹46.21 lakhs (standalone) and ₹56.29 lakhs (consolidated). - Basic/diluted EPS: ₹0.12 (standalo…
Vivanza Biosciences Board Meeting & Key Updates 🏛️ - Board meeting scheduled for November 11, 2025, to discuss unaudited standalone and consolidated financial results for the quarter ended September 30, 2025. - Resignation of CS Siddhi Shah, Company Secretary & Compliance Officer, effective Septe…
Vivanza Biosciences AGM 2025: Key Leadership Appointments Confirmed 🏛️ - Vivanza Biosciences held its 43rd Annual General Meeting (AGM) on September 25, 2025, via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). - Mr. Hitesh Pradeep Rijwani (DIN: 11030634) was approved as Non-Executive In…
Key Leadership Change at Vivanza Biosciences 🏢 - Ms. Siddhi Shah resigns as Company Secretary & Compliance Officer of Vivanza Biosciences Ltd. - Resignation effective from close of business on September 26, 2025. - Reason: Pursuing a career opportunity outside the company. - No other material rea…
Vivanza Biosciences Ltd Announces Key Updates & AGM Details 📅 - Board approved Director's Report and Secretarial Audit Report for FY 2024-25. - 43rd Annual General Meeting (AGM) scheduled for September 25, 2025, via Video Conferencing/Other Audio-Visual Means. - Cut-off date for AGM electronic vo…